|
|
Article: The U.S. Asthma/COPD Market: Rising Incidence and New Products Drive Market Growth; New Generation of Therapies Will Address Unmet Needs.
- Article from:
- PR Newswire
- Article date:
- November 5, 1998
CopyrightCOPYRIGHT 1998 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
ASHLAND, Ore., Nov. 5 /PRNewswire/ -- Over 30 million Americans suffer from the most common obstructive airway diseases: asthma and chronic obstructive pulmonary disease (COPD).
U.S. sales of prescription therapeutics for asthma and COPD exceeded $2.6 billion in 1997, and double digit revenue growth has been achieved in the last three years. Key market drivers are the rising incidence of the diseases and new product launches. The incidence of both asthma and COPD has increased 75% since 1980. Since the start of 1996, six new chemical entities, a new therapeutic category, and three new delivery devices have been approved.
The side effects and drug ...